349 related articles for article (PubMed ID: 20445015)
21. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
[TBL] [Abstract][Full Text] [Related]
22. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
Abassi ZA; Binah O; Youdim MB
Br J Pharmacol; 2004 Oct; 143(3):371-8. PubMed ID: 15339864
[TBL] [Abstract][Full Text] [Related]
25. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
[TBL] [Abstract][Full Text] [Related]
26. Rasagiline.
Siddiqui MA; Plosker GL
Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
28. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
29. Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2019 Mar; 60():146-152. PubMed ID: 30205936
[TBL] [Abstract][Full Text] [Related]
30. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
Thébault JJ; Guillaume M; Levy R
Pharmacotherapy; 2004 Oct; 24(10):1295-305. PubMed ID: 15628826
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
32. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
[TBL] [Abstract][Full Text] [Related]
33. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Parkinson Study Group
Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
[TBL] [Abstract][Full Text] [Related]
34. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2012 Apr; 119(4):405-14. PubMed ID: 22065207
[TBL] [Abstract][Full Text] [Related]
35. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
36. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Naoi M; Maruyama W; Inaba-Hasegawa K
Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
[TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanism and Structure-activity Relationship of the Inhibition Effect between Monoamine Oxidase and Selegiline Analogues.
Yang C; Wang X; Gao C; Liu Y; Ma Z; Zang J; Wang H; Liu L; Liu Y; Sun H; Wang W
Curr Comput Aided Drug Des; 2024; 20(5):474-485. PubMed ID: 37138424
[TBL] [Abstract][Full Text] [Related]
38. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
39. Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.
Götz ME; Breithaupt W; Sautter J; Kupsch A; Schwarz J; Oertel WH; Youdim MB; Riederer P; Gerlach M
J Neural Transm Suppl; 1998; 52():271-8. PubMed ID: 9564627
[TBL] [Abstract][Full Text] [Related]
40. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
